OncoArendi Therapeutics has signed an exclusive agreement

with one of the top 10 U.S. Universities for the development of inhibitors of new, validated biological targets for the treatment of anti-inflammatory diseases. Further details of this agreement cannot be disclosed at this time.

meatnetadmOncoArendi Therapeutics has signed an exclusive agreement
Czytaj więcej

OncoArendi Therapeutics has closed its angel investment round raising

through emission and acquisition of new shares, a total of 3.5 million PLN (approx. 1.1 million USD). Proceeds from this round will be used to supplement public financing in two ongoing discovery programs and launch a third program for the development of anti-inflammatory drug candidates.

meatnetadmOncoArendi Therapeutics has closed its angel investment round raising
Czytaj więcej